However, prostate cancer, especially metastatic castration–resistant prostate cancer, was regarded as a “cold” tumor with a low immune score and massive immunosuppressive components including Tregs and TGF-β, which means that patients are more likely to suffer immunotolerance and a poor response to immunotherapy (49–51). Here, TGFB1 is linked to neoplasm.